Canbridge Pharmaceuticals Inc
HKEX:1228
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Canbridge Pharmaceuticals Inc
HKEX:1228
|
CN |
|
M
|
Meridian Bioscience Inc
LSE:0K0K
|
US |
|
Intuitive Investments Group PLC
LSE:IIG
|
UK |
|
A
|
aXichem AB (publ)
STO:AXIC A
|
SE |
|
Taka Jewellery Holdings Ltd
SGX:42L
|
SG |
|
T
|
Tangshan Sanyou Chemical Industries Co Ltd
SSE:600409
|
CN |
|
Loop Energy Inc
TSX:LPEN
|
CA |
|
H
|
Helio SA
WSE:HEL
|
PL |
|
Dogan Burda Dergi Yayincilik ve Pazarlama AS
IST:DOBUR.E
|
TR |
|
Henkel AG & Co KGaA
XETRA:HEN
|
DE |
|
Northwest Pipe Co
NASDAQ:NWPX
|
US |
|
A
|
Axita Cotton Ltd
NSE:AXITA
|
IN |
Canbridge Pharmaceuticals Inc
CANbridge Pharmaceuticals Inc. operates as a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-12-10. The firm's main businesses are the development, production, promotion and sales of medical products. The firm's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The firm's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The firm is also engaged in the development of gene therapy.
CANbridge Pharmaceuticals Inc. operates as a rare disease-focused biopharmaceutical company committed to the research, development and commercialization of transformative therapies. The company is headquartered in Beijing, Beijing. The company went IPO on 2021-12-10. The firm's main businesses are the development, production, promotion and sales of medical products. The firm's main product is the glycosylated fusion protein CAN008 for the treatment of glioblastoma (GBM). The firm's products are mainly used in rare diseases such as Hunter's syndrome (MPS II), rare tumors and other fields. The firm is also engaged in the development of gene therapy.
